Abstract: Since 2006, vaccination against human papillomavirus (HPV) has been implemented in most developed countries.
Two vaccines have been successfully used: a bivalent vaccine targeting (bHPV)- related cancers and a quadrivalent
(qHPV) vaccine targeting both HPV-related cancers and genital warts. By 2015, a new nonavalent HPV (9vHPV)
vaccine was granted by marketing authorization, first in the USA in 2014 and subsequently in Europe. The efficiency
and/or immunogenicity of the 9vHPV has been assessed in the clinical studies which have been conducted so far and
rendered positive results. The real impact of the 9vHPV wide use in comparison with the bHPV or qHPV cannot be
specifically anticipated as it depends on different variables. However, the 5 further types in 9vHPV (HPV types 31, 33,
45, 52, and 58) increase the protection against cervical cancer to almost 90%. While, as mentioned above it is rather
difficult to precisely assess the impact of this additional aim, it is nonetheless its significance in which the clinical
studies conducted so far reported a successful rate of the 9vHPV vaccine use. Thus it can be argued that substituting the
qHPV with the 9vHPV may justify a significantly higher impact on HPV-related cancers both in females and males.
DOI:10.18643/gieu.2017.34